Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Charles Sawyers
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Disorders
Living Beings
Physiology
Genes & Molecular Sequences
Anatomy
Sign-in to see full Profile
Network (preview)
13
Tran, Chris
12
Mellinghoff, Ingo
9
Druker, Brian
9
Shah, Neil
8
Paquette, Ronald
8
Witte, Owen
7
Gorre, Mercedes
6
Vivanco, Igor
6
Whang, Young
6
Talpaz, Moshe
5
Capdeville, Renaud
5
Ellwood-Yen, Katharine
4
Cloughesy, Timothy
4
Mischel, Paul
4
Vessella, Robert
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Charles Sawyers (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Sawyers Charles L
Shifting paradigms: the seeds of oncogene addiction.
Nature medicine 2009;15(10):1158-61.
-
2009: Sawyers Charles L
Finding and drugging the vulnerabilities of RAS-dependent cancers.
Cell 2009;137(5):796-8.
-
2009: King Jennifer C; Xu Jin; Wongvipat John; Hieronymus Haley; Carver Brett S; Leung David H; Taylor Barry S; Sander Chris; Cardiff Robert D; Couto Suzana S; Gerald William L; Sawyers Charles L
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.
Nature genetics 2009;41(5):524-6.
-
2009: Tran Chris; Ouk Samedy; Clegg Nicola J; Chen Yu; Watson Philip A; Arora Vivek; Wongvipat John; Smith-Jones Peter M; Yoo Dongwon; Kwon Andrew; Wasielewska Teresa; Welsbie Derek; Chen Charlie Degui; Higano Celestia S; Beer Tomasz M; Hung David T; Scher Howard I; Jung Michael E; Sawyers Charles L
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Science (New York, N.Y.) 2009;324(5928):787-90.
-
2009: Welsbie Derek S; Xu Jin; Chen Yu; Borsu Laetitia; Scher Howard I; Rosen Neal; Sawyers Charles L
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.
Cancer research 2009;69(3):958-66.
-
2008: Shah Neil P; Kasap Corynn; Weier Christopher; Balbas Minna; Nicoll John M; Bleickardt Eric; Nicaise Claude; Sawyers Charles L
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Cancer cell 2008;14(6):485-93.
-
2008: Sawyers Charles L
Translational research: are we on the right track? 2008 American Society for Clinical Investigation Presidential Address.
The Journal of clinical investigation 2008;118(11):3798-801.
-
2008: Jin Ren Jie; Lho Yongsoo; Connelly Linda; Wang Yongqing; Yu Xiuping; Saint Jean Leshana; Case Thomas C; Ellwood-Yen Katharine; Sawyers Charles L; Bhowmick Neil A; Blackwell Timothy S; Yull Fiona E; Matusik Robert J
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.
Cancer research 2008;68(16):6762-9.
-
2008: Majumder Pradip K; Grisanzio Chiara; O'Connell Fionnuala; Barry Marc; Brito Joseph M; Xu Qing; Guney Isil; Berger Raanan; Herman Paula; Bikoff Rachel; Fedele Giuseppe; Baek Won-Ki; Wang Shunyou; Ellwood-Yen Katharine; Wu Hong; Sawyers Charles L; Signoretti Sabina; Hahn William C; Loda Massimo; Sellers William R
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.
Cancer cell 2008;14(2):146-55.
-
2008: Chen Yu; Sawyers Charles L; Scher Howard I
Targeting the androgen receptor pathway in prostate cancer.
Current opinion in pharmacology 2008;8(4):440-8.
-
2008: Sawyers Charles L
The cancer biomarker problem.
Nature 2008;452(7187):548-52.
-
2008: Sawyers Charles L
Something lost--something gained: the ASCI begins its second century.
The Journal of clinical investigation 2008;118(4):1213-4.
-
2008: Duncan Elizabeth A; Goetz Christine A; Stein Sarah J; Mayo Katie J; Skaggs Brian J; Ziegelbauer Karl; Sawyers Charles L; Baldwin Albert S
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
Molecular cancer therapeutics 2008;7(2):391-7.
-
2008: Cloughesy Tim F; Yoshimoto Koji; Nghiemphu Phioanh; Brown Kevin; Dang Julie; Zhu Shaojun; Hsueh Teli; Chen Yinan; Wang Wei; Youngkin David; Liau Linda; Martin Neil; Becker Don; Bergsneider Marvin; Lai Albert; Green Richard; Oglesby Tom; Koleto Michael; Trent Jeff; Horvath Steve; Mischel Paul S; Mellinghoff Ingo K; Sawyers Charles L
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
PLoS medicine 2008;5(1):e8.
-
2007: Kaelin William G; Sawyers Charles L; Mihich Enrico
Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical investigation in cancer.
Cancer research 2007;67(23):11102-5.
-
2007: Sawyers Charles L
Cancer: mixing cocktails.
Nature 2007;449(7165):993-6.
-
2007: Sawyers Charles L
Where lies the blame for resistance--tumor or host?
Nature medicine 2007;13(10):1144-5.
-
2007: Shah Neil P; Skaggs Brian J; Branford Susan; Hughes Timothy P; Nicoll John M; Paquette Ronald L; Sawyers Charles L
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
The Journal of clinical investigation 2007;117(9):2562-9.
-
2007: Jiao Jing; Wang Shunyou; Qiao Rong; Vivanco Igor; Watson Philip A; Sawyers Charles L; Wu Hong
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
Cancer research 2007;67(13):6083-91.
-
2007: Saldanha J; Silvy M; Beaufils N; Arlinghaus R; Barbany G; Branford S; Cayuela J-M; Cazzaniga G; Gonzalez M; Grimwade D; Kairisto V; Miyamura K; Lawler M; Lion T; Macintyre E; Mahon F-X; Muller M C; Ostergaard M; Pfeifer H; Saglio G; Sawyers C; Spinelli O; van der Velden V H J; Wang J Q; Zoi K; Patel V; Phillips P; Matejtschuk P; Gabert J
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(7):1481-7.
-
2007: Vivanco Igor; Palaskas Nicolaos; Tran Chris; Finn Stephen P; Getz Gad; Kennedy Norman J; Jiao Jing; Rose Joshua; Xie Wanling; Loda Massimo; Golub Todd; Mellinghoff Ingo K; Davis Roger J; Wu Hong; Sawyers Charles L
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.
Cancer cell 2007;11(6):555-69.
-
2006: Skaggs Brian J; Gorre Mercedes E; Ryvkin Ann; Burgess Michael R; Xie Yongming; Han Yun; Komisopoulou Evangelia; Brown Lauren M; Loo Joseph A; Landaw Elliot M; Sawyers Charles L; Graeber Thomas G
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(51):19466-71.
-
2006: Ellwood-Yen Katharine; Wongvipat John; Sawyers Charles
Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.
Cancer research 2006;66(21):10513-6.
-
2006: Wang Maria Y; Lu Kan V; Zhu Shaojun; Dia Ederlyn Q; Vivanco Igor; Shackleford Gregory M; Cavenee Webster K; Mellinghoff Ingo K; Cloughesy Timothy F; Sawyers Charles L; Mischel Paul S
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
Cancer research 2006;66(16):7864-9.
-
2006: Sawyers Charles L
Will kinase inhibitors have a dark side?
The New England journal of medicine 2006;355(3):313-5.
-
2006: Talpaz Moshe; Shah Neil P; Kantarjian Hagop; Donato Nicholas; Nicoll John; Paquette Ron; Cortes Jorge; O'Brien Susan; Nicaise Claude; Bleickardt Eric; Blackwood-Chirchir M Anne; Iyer Vishwanath; Chen Tai-Tsang; Huang Fei; Decillis Arthur P; Sawyers Charles L
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
The New England journal of medicine 2006;354(24):2531-41.
-
2006: Chandra Joya; Tracy Jeannette; Loegering David; Flatten Karen; Verstovsek Srdan; Beran Miloslav; Gorre Mercedes; Estrov Zeev; Donato Nicholas; Talpaz Moshe; Sawyers Charles; Bhalla Kapil; Karp Judith; Sausville Edward; Kaufmann Scott H
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Blood 2006;107(6):2501-6.
-
2006: Baek Sung Hee; Ohgi Kenneth A; Nelson Charles A; Welsbie Derek; Chen Charlie; Sawyers Charles L; Rose David W; Rosenfeld Michael G
Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(9):3100-5.
-
2006: Radich Jerald P; Dai Hongyue; Mao Mao; Oehler Vivian; Schelter Jan; Druker Brian; Sawyers Charles; Shah Neil; Stock Wendy; Willman Cheryl L; Friend Stephen; Linsley Peter S
Gene expression changes associated with progression and response in chronic myeloid leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(8):2794-9.
-
2006: Young Matthew A; Shah Neil P; Chao Luke H; Seeliger Markus; Milanov Zdravko V; Biggs William H; Treiber Daniel K; Patel Hitesh K; Zarrinkar Patrick P; Lockhart David J; Sawyers Charles L; Kuriyan John
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
Cancer research 2006;66(2):1007-14.
-
2006: Thomas George V; Tran Chris; Mellinghoff Ingo K; Welsbie Derek S; Chan Emily; Fueger Barbara; Czernin Johannes; Sawyers Charles L
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
Nature medicine 2006;12(1):122-7.
-
2006: Burgess Michael R; Sawyers Charles L
Treating imatinib-resistant leukemia: the next generation targeted therapies.
TheScientificWorldJournal 2006;6():918-30.
-
2005: Watson Philip A; Ellwood-Yen Katharine; King Jennifer C; Wongvipat John; Lebeau Michelle M; Sawyers Charles L
Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
Cancer research 2005;65(24):11565-71.
-
2005: Koochekpour Shahriar; Zhuang Yu-Jun; Beroukhim Rameen; Hsieh Chia-Ling; Hofer Matthias D; Zhau Haiyen E; Hiraiwa Masao; Pattan Daniel Y; Ware Joy L; Luftig Ronald B; Sandhoff Konrad; Sawyers Charles L; Pienta Kenneth J; Rubin Mark A; Vessella Robert L; Sellers William R; Sartor Oliver
Amplification and overexpression of prosaposin in prostate cancer.
Genes, chromosomes & cancer 2005;44(4):351-64.
-
2005: Mellinghoff Ingo K; Wang Maria Y; Vivanco Igor; Haas-Kogan Daphne A; Zhu Shaojun; Dia Ederlyn Q; Lu Kan V; Yoshimoto Koji; Huang Julie H Y; Chute Dennis J; Riggs Bridget L; Horvath Steve; Liau Linda M; Cavenee Webster K; Rao P Nagesh; Beroukhim Rameen; Peck Timothy C; Lee Jeffrey C; Sellers William R; Stokoe David; Prados Michael; Cloughesy Timothy F; Sawyers Charles L; Mischel Paul S
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
The New England journal of medicine 2005;353(19):2012-24.
-
2005: Scher Howard I; Sawyers Charles L
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(32):8253-61.
-
2005: Sawyers Charles L
Update on the use of imatinib mesylate.
Clinical advances in hematology & oncology : H&O 2005;3(10):757-8.
-
2005: Sawyers Charles L
Calculated resistance in cancer.
Nature medicine 2005;11(8):824-5.
-
2005: Carter Todd A; Wodicka Lisa M; Shah Neil P; Velasco Anne Marie; Fabian Miles A; Treiber Daniel K; Milanov Zdravko V; Atteridge Corey E; Biggs William H; Edeen Philip T; Floyd Mark; Ford Julia M; Grotzfeld Robert M; Herrgard Sanna; Insko Darren E; Mehta Shamal A; Patel Hitesh K; Pao William; Sawyers Charles L; Varmus Harold; Zarrinkar Patrick P; Lockhart David J
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(31):11011-6.
-
2005: Michor Franziska; Hughes Timothy P; Iwasa Yoh; Branford Susan; Shah Neil P; Sawyers Charles L; Nowak Martin A
Dynamics of chronic myeloid leukaemia.
Nature 2005;435(7046):1267-70.
-
2005: Kim Jung Hwa; Kim Bogyou; Cai Ling; Choi Hee June; Ohgi Kenneth A; Tran Chris; Chen Charlie; Chung Chin Ha; Huber Otmar; Rose David W; Sawyers Charles L; Rosenfeld Michael G; Baek Sung Hee
Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes.
Nature 2005;434(7035):921-6.
-
2005: Burgess Michael R; Skaggs Brian J; Shah Neil P; Lee Francis Y; Sawyers Charles L
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(9):3395-400.
-
2005: Chu Su; Xu Helen; Shah Neil P; Snyder David S; Forman Stephen J; Sawyers Charles L; Bhatia Ravi
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
Blood 2005;105(5):2093-8.
-
2005: Waldherr Christian; Mellinghoff Ingo K; Tran Chris; Halpern Benjamin S; Rozengurt Nora; Safaei Arash; Weber Wolfgang A; Stout David; Satyamurthy Nagichettiar; Barrio Jorge; Phelps Michael E; Silverman Daniel H; Sawyers Charles L; Czernin Johannes
Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(1):114-20.
-
2005: Graeber Thomas G; Sawyers Charles L
Cross-species comparisons of cancer signaling.
Nature genetics 2005;37(1):7-8.
-
2004: Thomas George V; Horvath Steve; Smith Bradley L; Crosby Katherine; Lebel Lori A; Schrage Matthew; Said Jonathan; De Kernion Jean; Reiter Robert E; Sawyers Charles L
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8351-6.
-
2004: Sawyers Charles
Targeted cancer therapy.
Nature 2004;432(7015):294-7.
-
2004: Mellinghoff Ingo K; Vivanco Igor; Kwon Andrew; Tran Chris; Wongvipat John; Sawyers Charles L
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.
Cancer cell 2004;6(5):517-27.
-
2004: Jamieson Catriona H M; Ailles Laurie E; Dylla Scott J; Muijtjens Manja; Jones Carol; Zehnder James L; Gotlib Jason; Li Kevin; Manz Markus G; Keating Armand; Sawyers Charles L; Weissman Irving L
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
The New England journal of medicine 2004;351(7):657-67.
-
2004: Shah Neil P; Tran Chris; Lee Francis Y; Chen Ping; Norris Derek; Sawyers Charles L
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Science (New York, N.Y.) 2004;305(5682):399-401.
-
2004: Mellinghoff Ingo K; Sawyers Charles L
TORward AKTually useful mouse models.
Nature medicine 2004;10(6):579-80.
-
2004: Peng Bin; Hayes Michael; Resta Debra; Racine-Poon Amy; Druker Brian J; Talpaz Moshe; Sawyers Charles L; Rosamilia Marianne; Ford John; Lloyd Peter; Capdeville Renaud
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):935-42.
-
2004: Chen Charlie D; Welsbie Derek S; Tran Chris; Baek Sung Hee; Chen Randy; Vessella Robert; Rosenfeld Michael G; Sawyers Charles L
Molecular determinants of resistance to antiandrogen therapy.
Nature medicine 2004;10(1):33-9.
-
2004: Gera Joseph F; Mellinghoff Ingo K; Shi Yijiang; Rettig Matthew B; Tran Chris; Hsu Jung-hsin; Sawyers Charles L; Lichtenstein Alan K
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.
The Journal of biological chemistry 2004;279(4):2737-46.
-
2003: Sawyers Charles L
Opportunities and challenges in the development of kinase inhibitor therapy for cancer.
Genes & development 2003;17(24):2998-3010.
-
2003: Sawyers Charles L
Will mTOR inhibitors make it as cancer drugs?
Cancer cell 2003;4(5):343-8.
-
2003: Shah Neil P; Sawyers Charles L
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
Oncogene 2003;22(47):7389-95.
-
2003: Ellwood-Yen Katharine; Graeber Thomas G; Wongvipat John; Iruela-Arispe M Luisa; Zhang JianFeng; Matusik Robert; Thomas George V; Sawyers Charles L
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
Cancer cell 2003;4(3):223-38.
-
2003: Choe Gheeyoung; Horvath Steve; Cloughesy Timothy F; Crosby Katherine; Seligson David; Palotie Aarno; Inge Landon; Smith Bradley L; Sawyers Charles L; Mischel Paul S
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
Cancer research 2003;63(11):2742-6.
-
2003: Bhatia Ravi; Holtz Melissa; Niu Ning; Gray Rachel; Snyder David S; Sawyers Charles L; Arber Daniel A; Slovak Marilyn L; Forman Stephen J
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Blood 2003;101(12):4701-7.
-
2003: Huron David R; Gorre Mercedes E; Kraker Alan J; Sawyers Charles L; Rosen Neal; Moasser Mark M
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1267-73.
-
2003: Yang Honghao; Berger Frank; Tran Chris; Gambhir Sanjiv S; Sawyers Charles L
MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts.
The Prostate 2003;55(1):39-47.
-
2002: Gorre Mercedes E; Ellwood-Yen Katharine; Chiosis Gabriela; Rosen Neal; Sawyers Charles L
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.
Blood 2002;100(8):3041-4.
-
2002: Berger Frank; Lee Yu-Po; Loening Andreas M; Chatziioannou Arion; Freedland Stephen J; Leahy Richard; Lieberman Jay R; Belldegrun Arie S; Sawyers Charles L; Gambhir Sanjiv S
Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease.
European journal of nuclear medicine and molecular imaging 2002;29(9):1225-36.
-
2002: Mellinghoff Ingo K; Tran Chris; Sawyers Charles L
Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.
Cancer research 2002;62(18):5254-9.
-
2002: Mellinghoff Ingo K; Sawyers Charles L
The emergence of resistance to targeted cancer therapeutics.
Pharmacogenomics 2002;3(5):603-23.
-
2002: Laitinen Sari; Karhu Ritva; Sawyers Charles L; Vessella Robert L; Visakorpi Tapio
Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization.
Genes, chromosomes & cancer 2002;35(1):66-73.
-
2002: Sawyers Charles L
Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(17):3568-9.
-
2002: Ottmann Oliver G; Druker Brian J; Sawyers Charles L; Goldman John M; Reiffers Jose; Silver Richard T; Tura Sante; Fischer Thomas; Deininger Michael W; Schiffer Charles A; Baccarani Michele; Gratwohl Alois; Hochhaus Andreas; Hoelzer Dieter; Fernandes-Reese Sofia; Gathmann Insa; Capdeville Renaud; O'Brien Stephen G
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Blood 2002;100(6):1965-71.
-
2002: Hess Patricia; Pihan German; Sawyers Charles L; Flavell Richard A; Davis Roger J
Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts.
Nature genetics 2002;32(1):201-5.
-
2002: Shah Neil P; Nicoll John M; Nagar Bhushan; Gorre Mercedes E; Paquette Ronald L; Kuriyan John; Sawyers Charles L
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Cancer cell 2002;2(2):117-25.
-
2002: Roumiantsev Sergei; Shah Neil P; Gorre Mercedes E; Nicoll John; Brasher Bradley B; Sawyers Charles L; Van Etten Richard A
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(16):10700-5.
-
2002: Paquette R L; Hsu N; Said J; Mohammed M; Rao N P; Shih G; Schiller G; Sawyers C; Glaspy J A
Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(8):1484-9.
-
2002: Thomas Miranda; Laura Richard; Hepner Karin; Guccione Ernesto; Sawyers Charles; Lasky Laurence; Banks Lawrence
Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation.
Oncogene 2002;21(33):5088-96.
-
2002: Gery Sigal; Sawyers Charles L; Agus David B; Said Jonathan W; Koeffler H Phillip
TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells.
Oncogene 2002;21(31):4739-46.
-
2002: Vivanco Igor; Sawyers Charles L
The phosphatidylinositol 3-Kinase AKT pathway in human cancer.
Nature reviews. Cancer 2002;2(7):489-501.
-
2002: Braziel Rita M; Launder Teresa M; Druker Brian J; Olson Susan B; Magenis R Ellen; Mauro Michael J; Sawyers Charles L; Paquette Ronald L; O'Dwyer Michael E
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
Blood 2002;100(2):435-41.
-
2002: Gorre Mercedes E; Sawyers Charles L
Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia.
Current opinion in hematology 2002;9(4):303-7.
-
2002: Sawyers Charles L
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.
Cancer cell 2002;1(5):413-5.
-
2002: Holtz Melissa S; Slovak Marilyn L; Zhang Feiyu; Sawyers Charles L; Forman Stephen J; Bhatia Ravi
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.
Blood 2002;99(10):3792-800.
-
2002: Chen Charlie D; Sawyers Charles L
NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer.
Molecular and cellular biology 2002;22(8):2862-70.
-
2002: Sawyers Charles L; Sausville Edward A
Overview: the art of cancer drug screening: molecular target versus milieu-based screens.
Current opinion in investigational drugs (London, England : 2000) 2002;3(3):478-81.
-
2002: Talpaz Moshe; Silver Richard T; Druker Brian J; Goldman John M; Gambacorti-Passerini Carlo; Guilhot Francois; Schiffer Charles A; Fischer Thomas; Deininger Michael W N; Lennard Anne L; Hochhaus Andreas; Ottmann Oliver G; Gratwohl Alois; Baccarani Michele; Stone Richard; Tura Sante; Mahon Francois-Xavier; Fernandes-Reese Sofia; Gathmann Insa; Capdeville Renaud; Kantarjian Hagop M; Sawyers Charles L
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood 2002;99(6):1928-37.
-
2002: Sawyers Charles L
Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
Cancer cell 2002;1(1):13-5.
-
2002: Sawyers Charles L
Rational therapeutic intervention in cancer: kinases as drug targets.
Current opinion in genetics & development 2002;12(1):111-5.
-
2001: Neshat M S; Mellinghoff I K; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons J J; Wu H; Sawyers C L
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(18):10314-9.
-
2001: Podsypanina K; Lee R T; Politis C; Hennessy I; Crane A; Puc J; Neshat M; Wang H; Yang L; Gibbons J; Frost P; Dreisbach V; Blenis J; Gaciong Z; Fisher P; Sawyers C; Hedrick-Ellenson L; Parsons R
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(18):10320-5.
-
2001: Gorre M E; Mohammed M; Ellwood K; Hsu N; Paquette R; Rao P N; Sawyers C L
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Science (New York, N.Y.) 2001;293(5531):876-80.
-
2001: Tsukasaki K; Miller C W; Greenspun E; Eshaghian S; Kawabata H; Fujimoto T; Tomonaga M; Sawyers C; Said J W; Koeffler H P
Mutations in the mitotic check point gene, MAD1L1, in human cancers.
Oncogene 2001;20(25):3301-5.
-
2001: Schiller G; Wong S; Lowe T; Snead G; Paquette R; Sawyers C; Wolin M; Kunkel L; Ting L; Li G; Territo M
Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(5):757-63.
-
2001: Druker B J; Sawyers C L; Kantarjian H; Resta D J; Reese S F; Ford J M; Capdeville R; Talpaz M
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
The New England journal of medicine 2001;344(14):1038-42.
-
2001: Druker B J; Talpaz M; Resta D J; Peng B; Buchdunger E; Ford J M; Lydon N B; Kantarjian H; Capdeville R; Ohno-Jones S; Sawyers C L
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
The New England journal of medicine 2001;344(14):1031-7.
-
2001: Shah N P; Sawyers C L
Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
Current opinion in investigational drugs (London, England : 2000) 2001;2(3):422-3.
-
2000: Whang Y E; Tran C; Henderson C; Syljuasen R G; Rozengurt N; McBride W H; Sawyers C L
c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(10):5486-91.
-
2000: Wu X; Hepner K; Castelino-Prabhu S; Do D; Kaye M B; Yuan X J; Wood J; Ross C; Sawyers C L; Whang Y E
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(8):4233-8.
-
2000: Neshat M S; Raitano A B; Wang H G; Reed J C; Sawyers C L
The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.
Molecular and cellular biology 2000;20(4):1179-86.
-
1999: Craft N; Chhor C; Tran C; Belldegrun A; DeKernion J; Witte O N; Said J; Reiter R E; Sawyers C L
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.
Cancer research 1999;59(19):5030-6.
-
1999: Huang W; Shostak Y; Tarr P; Sawyers C; Carey M
Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer.
The Journal of biological chemistry 1999;274(36):25756-68.
-
1999: Abreu-Martin M T; Chari A; Palladino A A; Craft N A; Sawyers C L
Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer.
Molecular and cellular biology 1999;19(7):5143-54.
-
1999: Schiller G; Lee M; Paquette R; Sawyers C; Khoubian F; Territo M
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission.
Leukemia & lymphoma 1999;33(5-6):475-84.
-
1999: Sawyers C L
Chronic myeloid leukemia.
The New England journal of medicine 1999;340(17):1330-40.
-
1999: Sawyers C L; Druker B
Tyrosine kinase inhibitors in chronic myeloid leukemia.
The cancer journal from Scientific American 1999;5(2):63-9.
-
1999: Craft N; Shostak Y; Carey M; Sawyers C L
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.
Nature medicine 1999;5(3):280-5.
-
1998: Sawyers C L
Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes.
Leukemia research 1998;22(12):1113-22.
-
1998: Wu X; Senechal K; Neshat M S; Whang Y E; Sawyers C L
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(26):15587-91.
-
1998: Senechal K; Heaney C; Druker B; Sawyers C L
Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells.
Molecular and cellular biology 1998;18(9):5082-90.
-
1998: Whang Y E; Wu X; Sawyers C L
Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene.
Journal of the National Cancer Institute 1998;90(11):859-61.
-
1998: Whang Y E; Wu X; Suzuki H; Reiter R E; Tran C; Vessella R L; Said J W; Isaacs W B; Sawyers C L
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(9):5246-50.
-
1998: Craft N; Sawyers C L
Mechanistic concepts in androgen-dependence of prostate cancer.
Cancer metastasis reviews 1998;17(4):421-7.
-
1997: Raitano A B; Whang Y E; Sawyers C L
Signal transduction by wild-type and leukemogenic Abl proteins.
Biochimica et biophysica acta 1997;1333(3):F201-16.
-
1997: Schiller G; Lee M; Miller T; Lill M; Mittal-Henkle A; Paquette R; Sawyers C; Territo M
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(9):1533-9.
-
1997: Dickens M; Rogers J S; Cavanagh J; Raitano A; Xia Z; Halpern J R; Greenberg M E; Sawyers C L; Davis R J
A cytoplasmic inhibitor of the JNK signal transduction pathway.
Science (New York, N.Y.) 1997;277(5326):693-6.
-
1997: Sawyers C L
Signal transduction pathways involved in BCR-ABL transformation.
Baillière's clinical haematology 1997;10(2):223-31.
-
1997: Klein K A; Reiter R E; Redula J; Moradi H; Zhu X L; Brothman A R; Lamb D J; Marcelli M; Belldegrun A; Witte O N; Sawyers C L
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice.
Nature medicine 1997;3(4):402-8.
-
1997: Sawyers C L
Molecular genetics of acute leukaemia.
Lancet 1997;349(9046):196-200.
-
1996: Senechal K; Sawyers C L
Signal transduction-based strategies for the treatment of chronic myelogenous leukemia.
Molecular medicine today 1996;2(12):503-9.
-
1996: Senechal K; Halpern J; Sawyers C L
The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene.
The Journal of biological chemistry 1996;271(38):23255-61.
-
1996: Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers C L
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Oncogene 1996;13(2):247-54.
-
1995: Raitano A B; Halpern J R; Hambuch T M; Sawyers C L
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(25):11746-50.
-
1995: Goga A; Liu X; Hambuch T M; Senechal K; Major E; Berk A J; Witte O N; Sawyers C L
p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase.
Oncogene 1995;11(4):791-9.
-
1994: Hathorn R W; Tso C L; Kaboo R; Pang S; Figlin R; Sawyers C; deKernion J B; Belldegrun A
In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer.
Cancer 1994;74(7):1904-11.
-
1994: Sawyers C L; Denny C T
Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about.
Cell 1994;77(2):171-3.
-
1994: Afar D E; Goga A; McLaughlin J; Witte O N; Sawyers C L
Differential complementation of Bcr-Abl point mutants with c-Myc.
Science (New York, N.Y.) 1994;264(5157):424-6.
-
1994: Sawyers C L; McLaughlin J; Goga A; Havlik M; Witte O
The nuclear tyrosine kinase c-Abl negatively regulates cell growth.
Cell 1994;77(1):121-31.
-
1994: Afar D E; Goga A; Cohen L; Sawyers C L; McLaughlin J; Mohr R N; Witte O N
Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL.
Cold Spring Harbor symposia on quantitative biology 1994;59():589-94.
-
1993: Sawyers C L
The role of myc in transformation by BCR-ABL.
Leukemia & lymphoma 1993;11 Suppl 1():45-6.
-
1993: Sawyers C L
Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.
Leukemia & lymphoma 1993;11 Suppl 2():101-3.
-
1992: Sawyers C L; Callahan W; Witte O N
Dominant negative MYC blocks transformation by ABL oncogenes.
Cell 1992;70(6):901-10.
-
1992: Sawyers C L; Gishizky M L; Quan S; Golde D W; Witte O N
Propagation of human blastic myeloid leukemias in the SCID mouse.
Blood 1992;79(8):2089-98.
-
1992: Sawyers C L; Golde D W; Quan S; Nimer S D
Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, leukocytosis, and eosinophilia.
Cancer 1992;69(6):1342-6.
-
1992: Sawyers C L
The bcr-abl gene in chronic myelogenous leukaemia.
Cancer surveys 1992;15():37-51.
-
1991: Sawyers C L; Denny C T; Witte O N
Leukemia and the disruption of normal hematopoiesis.
Cell 1991;64(2):337-50.
-
1990: Sawyers C L; Timson L; Kawasaki E S; Clark S S; Witte O N; Champlin R
Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(2):563-7.
Sign-in to see more
